Synthesis and biological evaluation of nitroxide labeled pyrimidines as Aurora kinase inhibitors

Bioorg Med Chem Lett. 2019 Mar 1;29(5):694-699. doi: 10.1016/j.bmcl.2019.01.034. Epub 2019 Jan 30.

Abstract

To find novel effective Aurora kinases inhibitors, a series of structurally interesting nitroxide labeled pyrimidines were synthesized and evaluated their anti-proliferative and Aurora kinases inhibitory activities. Among them, butyl 2-(3-((5-fluoro-2-((4-((1-oxyl-2,2,6,6-tetramethylpiperidin-4-yl)carbamoyl) phenyl) amino)pyrimidin-4-yl)amino)-1H-pyrazol-5-yl)acetate (22) possessed the most potent anti-proliferative effects against four carcinoma cell lines with IC50 values in range of 0.89-11.41 μM, and kinases inhibition against Aurora A and B with the IC50 values were 9.3 and 2.8 nM, respectively. Furthermore, compound 22 blocked the phosphorylation of Aurora A (T288), Aurora B (Thr232) and HisH3, decreased the expression of proteins TPX2, Eg5 and Bora, as well as disrupted the mitotic spindle formation in HeLa cells. Molecular docking studies indicated that compound 22 well interact with both Aurora A and B. The results showed that compound 22 is a potential anticancer agent as promising pan-Aurora kinase inhibitor.

Keywords: Anticancer; Aurora kinase; Nitroxides; Pyrimidine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aurora Kinases / antagonists & inhibitors*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Drug Screening Assays, Antitumor
  • Humans
  • Inhibitory Concentration 50
  • Nitrogen Oxides / chemistry*
  • Phosphorylation
  • Protein Kinase Inhibitors / chemical synthesis*
  • Protein Kinase Inhibitors / pharmacology*
  • Pyrimidines / chemistry*

Substances

  • Nitrogen Oxides
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Aurora Kinases